$ARCT News Article - Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency https://marketwirenews.com/news-releases/arct...25589.html
(0)
(0)
Arcturus Therapeutics Ltd. (ARCT) Stock Research Links